Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Femasys Inc
(NQ:
FEMY
)
1.300
+0.080 (+6.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Femasys Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
October 10, 2024
Company’s VP of Education and Global Training Named Chairman of ASRM Corporate Member Council
From
Femasys Inc.
Via
GlobeNewswire
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
October 08, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
October 02, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
September 12, 2024
Via
Benzinga
Deep Dive Into Femasys Stock: Analyst Perspectives (4 Ratings)
June 20, 2024
Via
Benzinga
Femasys Announces Infertility Clinic Customers from Coast to Coast
September 18, 2024
Leading medical clinics become key regional resources to offer FemaSeed infertility treatment
From
Femasys Inc.
Via
GlobeNewswire
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
September 11, 2024
Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women’s reproductive healthcare products
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
September 09, 2024
In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently...
From
Femasys Inc.
Via
GlobeNewswire
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
September 09, 2024
Via
Benzinga
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting
September 05, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
August 29, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
August 27, 2024
The Congresswoman representing Georgia’s 7th district in the U.S. House of Representatives toured Femasys’ facilities to gain a better understanding of our advancements for women’s reproductive health
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. at August 20th Virtual Investor Summit Microcap Event
August 19, 2024
Via
ACCESSWIRE
FEMY Stock Earnings: Femasys Misses EPS, Misses Revenue for Q2 2024
August 08, 2024
FEMY stock results show that Femasys missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
August 08, 2024
Company gained CE Mark approval for four of its women’s health products and completed buildout of commercial team for its infertility portfolio
From
Femasys Inc.
Via
GlobeNewswire
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
June 27, 2024
Leading women’s reproductive health conference directly follows the company’s EU CE Mark approval for four of its products
From
Femasys Inc.
Via
GlobeNewswire
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
June 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
June 20, 2024
Via
Benzinga
Gold Rises 1%; Accenture Shares Surge After Q3 Results
June 20, 2024
Via
Benzinga
Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
June 20, 2024
From
Femasys Inc.
Via
GlobeNewswire
EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says
June 17, 2024
Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market.
Via
Benzinga
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
May 17, 2024
Lee-Sepsick Discussed Company’s FemCerv® Endocervical Tissue Sampler and its Role in Cervical Cancer Diagnosis
From
Femasys Inc.
Via
GlobeNewswire
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council
May 16, 2024
Lee-Sepsick Discussed Atlanta-Based Biomedical Company’s Women’s Reproductive Health Products
From
Femasys Inc.
Via
GlobeNewswire
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q1 2024
May 09, 2024
FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
May 09, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
May 07, 2024
Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting
From
Femasys Inc.
Via
GlobeNewswire
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
April 18, 2024
From
Femasys Inc.
Via
GlobeNewswire
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023
March 28, 2024
FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.